Skip to content

Trial to Assess the Efficacy of the Comfort Plug™in Preventing Urinary Incontinence (COMFORT STUDY)

Validation Study: A Prospective, Non-Randomized, Single Arm Trial to Assess the Efficacy of the Comfort Plug™ in Preventing Urinary Incontinence in Male Subjects With Post Prostatectomy Urinary Incontinence (COMFORT STUDY)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03605459
Enrollment
30
Registered
2018-07-30
Start date
2014-02-04
Completion date
2018-04-03
Last updated
2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Incontinence

Brief summary

Validation Study: A Prospective, Non-Randomized, Single Arm Trial to Assess the Efficacy of the Comfort Plug™ in Preventing Urinary Incontinence in Male Subjects with Post Prostatectomy Urinary Incontinence (COMFORT STUDY)

Detailed description

This is a first-in-human, device assessment, feasibility study to assess the safety, effectiveness, comfort and usability of the prototype Comfort Plug™ for controlling urinary incontinence in male subjects. No drug treatment will be administered.

Interventions

DEVICEComfort Plug™

Sponsors

CMX Research
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male 18 years of age or older 2. At least 6 months post radical prostatectomy for localized prostate cancer 3. Cystoscopic evaluation of the lower urinary tract within 12 months of screening 4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status 5. Evidence of moderate to severe urinary incontinence as assessed by the investigator, requiring protective garments or pads 6. Post-surgical Prostate Specific Antigen (PSA) \<0.04

Exclusion criteria

1. Inability to insert the Comfort Plug™ into his own urethra and remove it 2. History of significant incontinence prior to radical prostatectomy 3. Evidence of incomplete bladder emptying post radical prostatectomy 4. Recurrent , refractory bacteruria 5. Urethral stricture disease. 6. History of meatal stenosis or phimosis 7. History of any other malignancy except basal cell skin cancer 8. Planned radiotherapy for post prostatectomy residual disease within the next 90 days 9. Evidence of neurogenic bladder dysfunction 10. Multiple sclerosis or previous spinal cord trauma/pathology resulting in any neurologic deficit that, in the opinion of the investigator, might compromise the outcome 11. Ongoing constipation 12. Use of anticoagulant or antiplatelet medications excluding low-dose Acetylsalicylic acid (ASA) 13. Hemophilia 14. Any cardiac condition that requires the use of pre-procedure antibiotic prophylaxis such as a mechanical valve 15. Currently receiving successful medical treatment for incontinence. 16. The usage of male urethral slings 17. Planning to travel by airplane during the course of the study

Design outcomes

Primary

MeasureTime frameDescription
To establish safety of the Comfort Plug30 daysSafety is characterized by the absence of complications and adverse events
International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)30 daysThe ICIQ is a psychometrically robust patient-completed questionnaire for evaluating the frequency, severity and impact of urinary incontinence (UI) on Quality of Life in men and women. The ICIQ-SF is scored from 0 to 21, with greater scores indicating increased severity of UI. The change from baseline (Visit Day 0) in the ICIQ-SF score at Visit Days 7 and 30 (cohort 1) or Visit Days 14 and 30 (subsequent cohorts) will be examined.
Weight of protective pads30 daysChange from baseline (Visit Day 0) in the weight of the protective pads a Visit Days 7 and 30 (cohort 1) or Visit Days 14 and 30 (subsequent cohorts).

Secondary

MeasureTime frameDescription
Incontinence Quality of Life Questionnaire (I-QOL)30 daysThe questionnaire has a scale of 22-110; The higher the score, the less incontinence is having a negative impact on the subject's Quality of Life. Change from baseline (Visit Day 0) in the I-QOL instrument scores at Visit Days 14 and 30 for i) avoidance and limiting behavior ii) psychosocial impacts iii) social embarrassment will be examined.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026